80 related articles for article (PubMed ID: 9685058)
1. Doxorubicin pharmacokinetics: the effect of abnormal liver biochemistry tests.
Twelves CJ; Dobbs NA; Gillies HC; James CA; Rubens RD; Harper PG
Cancer Chemother Pharmacol; 1998; 42(3):229-34. PubMed ID: 9685058
[TBL] [Abstract][Full Text] [Related]
2. Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry.
Dobbs NA; Twelves CJ; Gillies H; James CA; Harper PG; Rubens RD
Cancer Chemother Pharmacol; 1995; 36(6):473-6. PubMed ID: 7554038
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests.
Twelves CJ; Dobbs NA; Michael Y; Summers LA; Gregory W; Harper PG; Rubens RD; Richards MA
Br J Cancer; 1992 Oct; 66(4):765-9. PubMed ID: 1419619
[TBL] [Abstract][Full Text] [Related]
4. Indocyanine green clearance in critically ill patients.
Pollack DS; Sufian S; Matsumoto T
Surg Gynecol Obstet; 1979 Dec; 149(6):852-4. PubMed ID: 388703
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
[TBL] [Abstract][Full Text] [Related]
6. An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin.
Gabizon A; Isacson R; Rosengarten O; Tzemach D; Shmeeda H; Sapir R
Cancer Chemother Pharmacol; 2008 Apr; 61(4):695-702. PubMed ID: 17549475
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients].
Wihlm J; Limacher JM; Levêque D; Duclos B; Dufour P; Bergerat JP; Methlin G
Bull Cancer; 1997 Jun; 84(6):603-8. PubMed ID: 9295863
[TBL] [Abstract][Full Text] [Related]
8. A population model of epirubicin pharmacokinetics and application to dosage guidelines.
Ralph LD; Thomson AH; Dobbs NA; Twelves C
Cancer Chemother Pharmacol; 2003 Jul; 52(1):34-40. PubMed ID: 12764671
[TBL] [Abstract][Full Text] [Related]
9. A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors.
Planting AS; Sonneveld P; van der Gaast A; Sparreboom A; van der Burg ME; Luyten GP; de Leeuw K; de Boer-Dennert M; Wissel PS; Jewell RC; Paul EM; Purvis NB; Verweij J
Cancer Chemother Pharmacol; 2005 Jan; 55(1):91-9. PubMed ID: 15565444
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
Tranchand B; Catimel G; Lucas C; Sarkany M; Bastian G; Evene E; Guastalla JP; Négrier S; Rebattu P; Dumortier A; Foy M; Grossin F; Mazier B; Froudarakis M; Barbet N; Clavel M; Ardiet C
Cancer Chemother Pharmacol; 1998; 41(4):281-91. PubMed ID: 9488597
[TBL] [Abstract][Full Text] [Related]
11. Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy.
Rudek MA; Sparreboom A; Garrett-Mayer ES; Armstrong DK; Wolff AC; Verweij J; Baker SD
Eur J Cancer; 2004 May; 40(8):1170-8. PubMed ID: 15110880
[TBL] [Abstract][Full Text] [Related]
12. [Populational pharmacokinetics of doxorubicin applied to personalised its dosing in cancer patients].
Escudero-Ortiz V; Ramón-López A; Duart MA; Pérez-Ruixo JJ; Valenzuela B
Farm Hosp; 2012; 36(4):282-91. PubMed ID: 22129650
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic study on the hepatic uptake of indocyanine green in cirrhotic patients.
Kawasaki S; Sugiyama Y; Iga T; Hanano M; Sanjo K; Beppu T; Idezuki Y
Am J Gastroenterol; 1985 Oct; 80(10):801-6. PubMed ID: 4036939
[TBL] [Abstract][Full Text] [Related]
14. Lattice intrahepatic doxorubicin with and without in-flow occlusion: a pharmacokinetic study of direct liver injection.
Averbach A; Stuart OA; Chang D; Sugarbaker PH
Eur J Surg Oncol; 2000 Feb; 26(1):73-9. PubMed ID: 10718184
[TBL] [Abstract][Full Text] [Related]
15. Phase I study and pharmacokinetics of menogaril (NSC 269148) in patients with hepatic dysfunction.
Egorin MJ; Conley BA; Forrest A; Zuhowski EG; Sinibaldi V; Van Echo DA
Cancer Res; 1987 Nov; 47(22):6104-10. PubMed ID: 2959359
[TBL] [Abstract][Full Text] [Related]
16. Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients.
La-Beck NM; Zamboni BA; Gabizon A; Schmeeda H; Amantea M; Gehrig PA; Zamboni WC
Cancer Chemother Pharmacol; 2012 Jan; 69(1):43-50. PubMed ID: 21590446
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass.
Barpe DR; Rosa DD; Froehlich PE
Eur J Pharm Sci; 2010 Nov; 41(3-4):458-63. PubMed ID: 20688160
[TBL] [Abstract][Full Text] [Related]
18. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics.
Varela M; Real MI; Burrel M; Forner A; Sala M; Brunet M; Ayuso C; Castells L; Montañá X; Llovet JM; Bruix J
J Hepatol; 2007 Mar; 46(3):474-81. PubMed ID: 17239480
[TBL] [Abstract][Full Text] [Related]
19. Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme.
Dobbs NA; Twelves CJ; Gregory W; Cruickshanka C; Richards MA; Rubens RD
Eur J Cancer; 2003 Mar; 39(5):580-6. PubMed ID: 12628836
[TBL] [Abstract][Full Text] [Related]
20. Augmentation of hepatic doxorubicin extraction with extracorporeal filtration avoids the dose-dependent, nonlinear increase in AUC observed with systemic administration.
Sturgill MG; Brenner DE; August DA
Cancer Chemother Pharmacol; 1998; 41(3):193-200. PubMed ID: 9443635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
